Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 4.7x - 5.2x | 4.9x |
| Historical Pb Multiple | 4.2x - 9.8x | 5.7x |
| Fair Value | €32.78 - €36.24 | €34.51 |
| Upside | -7.5% - 2.3% | -2.6% |
| Benchmarks | - | Full Ticker |
| Bristol-Myers Squibb Company | - | NYSE:BMY |
| GSK plc | - | OTCPK:GLAX.F |
| Novartis AG | - | OTCPK:NVSE.F |
| Johnson & Johnson | - | KAS:JNJ_KZ |
| Roche Holding AG | - | OTCPK:RHHV.F |
| Chugai Pharmaceutical Co., Ltd. | - | DB:CUP |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| BMY | GLAX.F | NVSE.F | JNJ_KZ | RHHV.F | CUP | |||
| NYSE:BMY | OTCPK:GLAX.F | OTCPK:NVSE.F | KAS:JNJ_KZ | OTCPK:RHHV.F | DB:CUP | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | -11.1% | 10.8% | -1.4% | -9.3% | 19.7% | ||
| 3Y CAGR | NM- | -8.1% | -19.5% | -7.5% | -15.9% | 8.5% | ||
| Latest Twelve Months | 177.2% | -15.1% | 35.4% | 38.3% | -11.2% | 11.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 2.1% | 23.8% | 27.4% | 24.8% | 20.6% | 30.1% | ||
| Prior Fiscal Year | 17.8% | 16.2% | 18.4% | 15.6% | 19.0% | 29.3% | ||
| Latest Fiscal Year | -18.5% | 8.2% | 23.1% | 15.8% | 13.3% | 33.1% | ||
| Latest Twelve Months | 10.6% | 10.8% | 24.7% | 25.0% | 14.9% | 33.1% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 3.8% | 30.9% | 22.9% | 23.3% | 40.6% | 24.9% | ||
| Prior Fiscal Year | 26.5% | 41.2% | 16.2% | 18.3% | 40.1% | 21.3% | ||
| Latest Twelve Months | 29.3% | 23.5% | 32.6% | 30.2% | 32.7% | 21.2% | ||
| Next Fiscal Year | 64.8% | 43.3% | 40.4% | 34.0% | 45.1% | 20.9% | ||
| Two Fiscal Years Forward | 43.3% | 38.5% | 42.3% | 30.8% | 38.9% | 19.9% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 2.0x | 1.8x | 4.1x | 4.6x | 3.3x | 8.4x | ||
| Price / LTM EPS | 18.6x | 16.4x | 16.5x | 18.4x | 22.4x | 25.4x | ||
| Price / Book | 5.4x | 3.8x | 5.4x | 5.3x | 7.4x | 5.1x | ||
| Price / Fwd Book | 3.8x | 3.3x | 5.2x | 5.1x | 5.4x | 4.6x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 3.8x | 5.4x | 7.4x | |||||
| Historical P/B Ratio | 4.2x | 5.7x | 9.8x | |||||
| Selected P/B Multiple | 4.7x | 4.9x | 5.2x | |||||
| (x) Book Value | 1,985,127 | 1,985,127 | 1,985,127 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | BMY | GLAX.F | NVSE.F | JNJ_KZ | RHHV.F | CUP | |
| Value of Common Equity | 93,528 | 56,228 | 221,868 | 421,339 | 210,776 | 10,015,437 | |
| (/) Shares Outstanding | 2,035.4 | 4,012.1 | 1,935.9 | 2,408.3 | 850.3 | 1,645.7 | |
| Implied Stock Price | 45.95 | 14.01 | 114.61 | 174.95 | 247.88 | 6,085.81 | |
| FX Conversion Rate to Trading Currency | 1.00 | 0.75 | 1.00 | 1.00 | 0.81 | 171.77 | |
| Implied Stock Price (Trading Cur) | 45.95 | 18.80 | 114.61 | 174.95 | 305.00 | 35.43 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 0.75 | 1.00 | 1.00 | 0.81 | 171.77 | |